The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
MINYM can be safely used by patients above 9 years of age.
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Subscribe To Our Newsletter & Stay Updated
